ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 133.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,378 shares of the biotechnology company’s stock after acquiring an additional 4,224 shares during the quarter. Nisa Investment Advisors LLC’s holdings in ADMA Biologics were worth $127,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Xponance Inc. raised its stake in shares of ADMA Biologics by 43.5% during the second quarter. Xponance Inc. now owns 18,468 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 5,597 shares during the period. Marshall Wace LLP increased its position in shares of ADMA Biologics by 44.1% during the second quarter. Marshall Wace LLP now owns 26,800 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 8,203 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of ADMA Biologics by 17.1% in the second quarter. The Manufacturers Life Insurance Company now owns 129,739 shares of the biotechnology company’s stock worth $1,450,000 after acquiring an additional 18,977 shares in the last quarter. Algert Global LLC boosted its holdings in ADMA Biologics by 831.6% in the second quarter. Algert Global LLC now owns 118,290 shares of the biotechnology company’s stock valued at $1,322,000 after purchasing an additional 105,593 shares during the last quarter. Finally, Creative Planning grew its stake in ADMA Biologics by 73.9% during the 2nd quarter. Creative Planning now owns 36,147 shares of the biotechnology company’s stock valued at $404,000 after purchasing an additional 15,363 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 1.7 %

Shares of ADMA Biologics stock opened at $16.10 on Friday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $3.81 billion, a price-to-earnings ratio of 57.50 and a beta of 0.76. ADMA Biologics, Inc. has a twelve month low of $5.02 and a twelve month high of $23.64. The business’s 50 day simple moving average is $18.31 and its 200-day simple moving average is $17.54.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period last year, the firm posted $0.01 EPS. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

Insider Activity

In related news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.